Moses Makunje
Direttore Finanziario/CFO presso NUVATION BIO INC.
Patrimonio netto: 27 803 $ in data 30/04/2024
Posizioni attive di Moses Makunje
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NUVATION BIO INC. | Comptroller/Controller/Auditor | 27/11/2023 | - |
| Direttore Finanziario/CFO | 27/11/2023 | - | |
| Corporate Officer/Principal | 01/07/2020 | 27/11/2023 |
Storia della carriera di Moses Makunje
Precedenti posizioni note di Moses Makunje
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Maze Therapeutics, Inc.
 Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01/03/2019 | 01/07/2020 |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
Posizioni
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
| Corporate Officer/Principal | 1 |
Settori
| Health Technology | 2 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| NUVATION BIO INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Maze Therapeutics, Inc.
Maze Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA. | Commercial Services |
- Borsa valori
- Insiders
- Moses Makunje
- Esperienza
